Anorectic drugs and pulmonary hypertension from the bedside to the bench

American Journal of the Medical Sciences

Volumn 321, Issue 4, 2001, Pages 292-299

  Michelakis, Evangelos D ^a,c   Weir, E Kenneth ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

5 Hydroxytryptamine; Aminorex; Dexfenfluramine; Fenfluramine; Kv channels; Primary pulmonary hypertension

Indexed keywords

4 AMINOPYRIDINE; AMINOREX; AMPHETAMINE DERIVATIVE; ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; POTASSIUM CHANNEL; SEROTONIN;

CELL PROLIFERATION; CONFERENCE PAPER; DRUG MARKETING; DRUG MECHANISM; DRUG USE; EPIDEMIC; HUMAN; LUNG RESISTANCE; MUSCLE CELL; NEUROTRANSMISSION; OBESITY; PATHOGENESIS; POTASSIUM CURRENT; PULMONARY ARTERY OCCLUSION; PULMONARY HYPERTENSION; SEROTONINERGIC SYSTEM; VASOCONSTRICTION; WEIGHT REDUCTION;

EID: 0035057728     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200104000-00009     Document Type: Conference Paper

References (62)

1. Obesity, dexfenfluramine, and pulmonary hypertension. A lesson not learned?
2. Valvular heart disease associated with fenfluramine-phentermine
3. Further cases of valvular heart disease associated with fenfluramine-phentermine
4. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs
5. Myocardial infarction associated with the use of dexfenfluramine
6. Digital necrosis associated with dexfenfluramine
7. Valvular heart disease associated with fenfluramine-phentermine
8. Mechanisms of disease: Ion channels - Basic science and clinical disease
9. The long QT syndrome: Ion channel diseases of the heart
10. Loss of functional KATP channels in pancreatic beta-cells causes persistent hyperinsulinemic hypoglycemia of infancy
11. Ion channels in vascular smooth muscle: Alterations in essential hypertension
12. Remission of high blood pressure reverses arterial potassium channel alterations
13. + channels in the cerebral microcirculation of genetically hypertensive rats: Evidence for their protection against cerebral vasospasm
14. + channel subunit mRNAs in ventricles of renovascular hypertensive rats
15. Molecular basis of transient outward potassium current downregulation in human heart failure: A decrease in Kv4.3 mRNA correlates with a reduction in current density
16. Increased plasma serotonin in primary pulmonary hypertension
17. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine
18. + channel gene transcription in primary pulmonary hypertension
19. Dysfunctional voltage-gated potassium channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension
20. Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: Role of serotonin
21. Aminorex and the pulmonary circulation
22. Epidemiologische untersuchungen zum zusammenhang swishen appetitzueglere inhahme und pimaer vasculaer pulmonaler hypertonie
23. Pulmonary hypertension and fenfluramine
24. A case of chronic pulmonary hypertension after fenfluramine intake
25. Irreversible pulmonary hypertension after treatment with fenfluramine
26. Pulmonary hypertension and fenfluramine
27. Primary pulmonary hypertension and fenfluramine use
28. Dexfenfluramine: A review of its pharmacologic properties and therapeutic potential in obesity
29. Appetite-suppressant drugs and the risk of primary pulmonary hypertension
30. Complex vascular lesions at autopsy in a patient with phentermine-fenfluramine use and rapidly progressing pulmonary hypertension
31. Aminorex, fenfluramine and chlorphentermine are serotonin transporter substrates: Implications for primary pulmonary hypertension
32. Primary pulmonary hypertension
33. Anorexic agents aminorex, fenfluramine and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction
34. Release of platelet 5-HT by some anorexic and other sympathomimetics and their acetyl derivatives
35. Dexfenfluramine and 4-aminopyridine (an inhibitor of voltage-gated potassium channels) increase serotonin release from human platelets
36. Physiological roles and properties of potassium channels in arterial smooth muscle cells
37. Molecular identification of the role of voltage-gated K channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes
38. Differential distribution of electrophysiologically distinct myocytes in conduit and resistance arteries determines their response to nitric oxide and hypoxia
39. + channels in pulmonary arterial smooth muscle cells
40. The mechanism of acute hypoxic pulmonary vasoconstriction: The tale of two channels
41. + channels and membrane depolarization regulate accumulation of the cyclin-dependent kinase inhibitors p27 (Kip1) and p21 (CIP1) in glial progenitor cells
42. 2+ influx in carcinoma cells of colon cancer
43. Potassium channel diversity in vascular smooth muscle cells
44. + channels in human pulmonary artery smooth muscle cells
45. Dexfenfluramine elevates systemic blood pressure by inhibiting potassium currents in vascular smooth muscle cells
46. Effects of the anorectic agent dexfenfluramine and 4-aminopyridine of the ductus arteriosus during development
47. + channels by dexfenfluramine (Redux)
48. A role for potassium channels in smooth muscle cells and platelets in the etiology of primary pulmonary hypertension
49. Kv2.1/Kv9.3, a novel ATP-dependent delayed-rectifier K channel in oxygen-sensitive pulmonary artery myocytes
50. Dexfenfluramine increases pulmonary artery smooth muscle intracellular calcium, independent of membrane potential
51. Effects of chronic dexfenfluramine treatment on pulmonary hemodynamics in dogs
52. Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease
53. Handling of bioactive materials by the lung
54. Effect of dexfenfluramine treatment in rats exposed to acute and chronic hypoxia
55. Effects of chlorphentermine and phentermine on the pulmonary disposition of 5-HT in the rat in vivo
56. Nitric oxide deficiency in pulmonary hypertension associated with use of the anorectic agents fenfluramine and dexfenfluramine
57. Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension
58. Prevalence of obesity
59. Sibutramine. A review of its contribution to the management of obesity
60. Anti-obesity drugs: What does sibutramine offer? An analysis of its potential contribution to obesity treatment
61. American Heart Association urges caution on a new diet drug